{"id":745338,"date":"2016-08-02T16:00:00","date_gmt":"2016-08-02T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/"},"modified":"2025-11-07T01:25:42","modified_gmt":"2025-11-07T06:25:42","slug":"mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1"},"content":{"rendered":"<p class=\"bwalignc\">       Approval Based on Trial Results Demonstrating Superior Overall        Survival Compared to Chemotherapy in Previously-Treated Patients     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the European Commission (EC) has approved KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, at a dose of 2 mg\/kg<br \/>\n      every three weeks, for patients with locally advanced or metastatic<br \/>\n      non-small cell lung cancer (NSCLC) in patients whose tumors express<br \/>\n      PD-L1 and who have received at least one prior chemotherapy regimen.<br \/>\n      Patients with EGFR or ALK positive tumor mutations should also have<br \/>\n      received approved therapy for these mutations prior to receiving<br \/>\n      KEYTRUDA. The EC approval allows marketing of KEYTRUDA in all 28 EU<br \/>\n      member states.\n    <\/p>\n<p>\n      The approval is based on findings from KEYNOTE-010, a pivotal study<br \/>\n      which showed KEYTRUDA significantly improved overall survival (OS)<br \/>\n      compared to standard of care chemotherapy.\n    <\/p>\n<p>\n      \u201cThis approval provides an important new treatment regimen for patients<br \/>\n      in Europe with advanced lung cancer, one of the most common and<br \/>\n      challenging cancers,\u201d said Dr. Roger Dansey, senior vice president and<br \/>\n      therapeutic area head, oncology late-stage development, Merck Research<br \/>\n      Laboratories. \u201cIn the KEYNOTE-010 trial, patients with advanced lung<br \/>\n      cancer who had failed prior regimens experienced improved overall<br \/>\n      survival when treated with KEYTRUDA as compared with those treated with<br \/>\n      traditional chemotherapy.\u201d\n    <\/p>\n<p>\n      \u201cThe survival benefit for KEYTRUDA observed in previously-treated<br \/>\n      patients who express PD-L1 is promising,\u201d said Dr. Luis Paz-Ares, chair<br \/>\n      of the medical oncology department, Hospital Universitario, Madrid,<br \/>\n      Spain. \u201cThere is a significant unmet need for lung cancer patients,&nbsp;and<br \/>\n      with this approval,&nbsp;we now have a new personalized treatment option<br \/>\n      which uses biomarker testing to predict which patients are most likely<br \/>\n      to benefit from treatment.\u201d\n    <\/p>\n<p>\n      <b>About KEYNOTE-010<\/b>\n    <\/p>\n<p>\n      KEYNOTE-010 is a global, open-label, randomized, pivotal phase 2\/3 study<br \/>\n      evaluating KEYTRUDA (pembrolizumab) (2 mg\/kg or 10 mg\/kg every three<br \/>\n      weeks) compared to standard of care chemotherapy (docetaxel, 75 mg\/m<sup>2<\/sup>&nbsp;every<br \/>\n      three weeks) in 1,033 patients with squamous and non-squamous NSCLC who<br \/>\n      experienced disease progression after platinum-containing systemic<br \/>\n      therapy and whose tumors expressed PD-L1. The primary endpoints were OS<br \/>\n      and progression-free survival (PFS) and were assessed based on patients<br \/>\n      with any level of PD-L1 expression (greater than or equal to one<br \/>\n      percent) and in patients whose tumors express higher levels of PD-L1<br \/>\n      (greater than or equal to 50 percent) \u2013 as reflected by tumor proportion<br \/>\n      score (TPS).\n    <\/p>\n<p>\n      In the total study population (all levels of PD-L1 expression), both<br \/>\n      doses of KEYTRUDA studied significantly improved OS compared with<br \/>\n      docetaxel. Specifically, KEYTRUDA resulted in a 29 percent improvement<br \/>\n      in OS for the 2 mg\/kg dose (HR 0.71 [95% CI, 0.58-0.88; P=0.001]) and a<br \/>\n      39 percent improvement in OS for the 10 mg\/kg dose (HR 0.61 [95% CI,<br \/>\n      0.49-0.75; P&lt;0.001]), compared to docetaxel. Median OS for KEYTRUDA was<br \/>\n      10.4 months (95% CI, 9.4-11.9) and 12.7 months (95% CI, 10.0-17.3),<br \/>\n      respectively, compared to 8.5 months for docetaxel (95% CI, 7.5-9.8).\n    <\/p>\n<p>\n      Among patients with higher levels of PD-L1 expression (a TPS score of 50<br \/>\n      percent or greater), OS was superior for both KEYTRUDA doses compared<br \/>\n      with docetaxel. Specifically, KEYTRUDA improved OS by 46 percent for the<br \/>\n      2 mg\/kg dose (HR 0.54 [95% CI, 0.38-0.77; P=0.001]) and by 50 percent<br \/>\n      for the 10 mg\/kg dose (HR 0.50 [95% CI, 0.36-0.70; P&lt;0.001]), compared<br \/>\n      to docetaxel. Median OS for KEYTRUDA (2 mg\/kg and 10 mg\/kg,<br \/>\n      respectively) was 14.9 months (95% CI, 10.4 to not reached) and 17.3<br \/>\n      months (95% CI, 11.8 to not reached), compared to 8.2 months for<br \/>\n      docetaxel (95% CI, 6.4-10.7).\n    <\/p>\n<p>\n      Among patients in the total study population treated with KEYTRUDA (2<br \/>\n      mg\/kg and 10 mg\/kg, respectively), median PFS was 3.9 months (95% CI,<br \/>\n      3.1-4.1) and 4.0 months (95% CI, 2.6-4.3), compared to 4.0 months for<br \/>\n      docetaxel (95% CI, 3.1-4.2). KEYTRUDA numerically reduced the risk of<br \/>\n      progression or death (PFS) at both doses (HR 0.88 [95% CI, 0.73-1.04]<br \/>\n      for 2 mg\/kg; HR 0.79 [95% CI, 0.66-0.94] for 10 mg\/kg). PFS results in<br \/>\n      the overall population were not statistically significant for either<br \/>\n      dose based on protocol-specified statistical testing requirements.\n    <\/p>\n<p>\n      Patients with higher levels of PD-L1 expression who were treated with<br \/>\n      KEYTRUDA had significantly prolonged PFS compared to docetaxel (HR 0.58<br \/>\n      [95% CI, 0.43-0.77; P=0.001] for 2 mg\/kg; HR 0.59 [95% CI, 0.45-0.78;<br \/>\n      P&lt;0.001] for 10 mg\/kg). Among patients treated with KEYTRUDA<br \/>\n      (pembrolizumab) (2 mg\/kg and 10 mg\/kg, respectively), median PFS was 5.2<br \/>\n      months (95% CI, 4.0-6.5) and 5.2 months (95% CI, 4.1-8.1), compared to<br \/>\n      4.1 months for docetaxel (95% CI, 3.6-4.3).\n    <\/p>\n<p>\n      The safety analysis supporting the European approval of KEYTRUDA was<br \/>\n      based on 2,799 patients with advanced melanoma or NSCLC across three<br \/>\n      doses (2 mg\/kg every three weeks or 10 mg\/kg every two or three weeks)<br \/>\n      in studies KEYNOTE-001, KEYNOTE-002 and KEYNOTE-010 combined. The most<br \/>\n      common adverse reactions (&gt;10%) with KEYTRUDA were fatigue (24%), rash<br \/>\n      (19%), pruritus (18%), diarrhea (12%), nausea (11%) and arthralgia<br \/>\n      (10%). The majority of adverse reactions reported were of Grade 1 or 2<br \/>\n      severity. The most serious adverse reactions were immune-related adverse<br \/>\n      reactions and severe infusion-related reactions.\n    <\/p>\n<p>\n      \u201cWe are thrilled that the European Union will now have a new treatment<br \/>\n      option for certain patients with advanced non-small cell lung cancer who<br \/>\n      have not responded to chemotherapy,\u201d said Stefania Vallone, president,<br \/>\n      Lung Cancer Europe. \u201cLung cancer represents the leading cause of cancer<br \/>\n      death worldwide, and this milestone underscores the importance of<br \/>\n      innovation and commitment to developing new treatments that can have a<br \/>\n      positive impact for patients living with this disease.\u201d\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast, and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small cell and small cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      relative survival rate for patients suffering from highly advanced,<br \/>\n      metastatic (Stage IV) lung cancers is estimated to be two percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100 mg in the U.S.<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is also indicated for the treatment of patients<br \/>\n      with advanced non-small cell lung cancer (NSCLC) whose tumors express<br \/>\n      PD-L1 as determined by an FDA-approved test with disease progression on<br \/>\n      or after platinum-containing chemotherapy. Patients with EGFR or ALK<br \/>\n      genomic tumor aberrations should have disease progression on<br \/>\n      FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg as an intravenous infusion<br \/>\n      over 30 minutes every three weeks for the approved indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis occurred in 19 (3.5%) of 550 patients,<br \/>\n      including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis<br \/>\n      and occurred more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients, including<br \/>\n      Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as clinically indicated.<br \/>\n      Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3 or 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%) hyperthyroidism. Hypothyroidism occurred in 38 (6.9%)<br \/>\n      of 550 patients, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA (pembrolizumab) and administer anti-hyperglycemics<br \/>\n      in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients. Serious adverse reactions occurred in 38% of patients. The<br \/>\n      most frequent serious adverse reactions reported in at least 2% of<br \/>\n      patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism,<br \/>\n      and pneumonitis. The most common adverse reactions (reported in at least<br \/>\n      20% of patients) were fatigue (44%), cough (29%), decreased appetite<br \/>\n      (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 300 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=9ddf2e3aba9721a684db8b69a142b809\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=1a50a2b69c51b63e6db6428bd84cbde5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=d2054c18d7c783fcb56013a676551e7f\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=550f3f84712e6d24f56e0bb0c3723fa6\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=f06452b889d976a9339e362f80d57377\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=df92dc0b0a0aac6f97698a52b4accbe5\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=05240cd0f49f5674d8d890bfc8309534\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=9cc3f6d19b529cd4b64a0b709888a4c9\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51389167&amp;newsitemid=20160802006940&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=88b00d2a45072b23efe24dbf03d60ca7\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160802006940r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, at a dose of 2 mg\/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received approved therapy for these mutations prior to receiving KEYTRUDA. The EC approval allows marketing of KEYTRUDA in all 28 EU member states. The approval is based on findings from KEYNOTE-010, a pivotal study which showed KEYTRUDA significantly improved overall survival (OS) compared to standard of care chemotherapy. \u201cThis approval provides an important new treatment regimen for patients in Europe with advanced lung cancer, one of the most common and challenging cancers,\u201d said Dr. Roger Dansey,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745338","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, at a dose of 2 mg\/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received approved therapy for these mutations prior to receiving KEYTRUDA. The EC approval allows marketing of KEYTRUDA in all 28 EU member states. The approval is based on findings from KEYNOTE-010, a pivotal study which showed KEYTRUDA significantly improved overall survival (OS) compared to standard of care chemotherapy. \u201cThis approval provides an important new treatment regimen for patients in Europe with advanced lung cancer, one of the most common and challenging cancers,\u201d said Dr. Roger Dansey,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-08-02T16:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, at a dose of 2 mg\/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received approved therapy for these mutations prior to receiving KEYTRUDA. The EC approval allows marketing of KEYTRUDA in all 28 EU member states. The approval is based on findings from KEYNOTE-010, a pivotal study which showed KEYTRUDA significantly improved overall survival (OS) compared to standard of care chemotherapy. \u201cThis approval provides an important new treatment regimen for patients in Europe with advanced lung cancer, one of the most common and challenging cancers,\u201d said Dr. Roger Dansey,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:42+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-08-02T16:00:00+00:00","dateModified":"2025-11-07T06:25:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e662ee5a-cc35-4383-8fb4-a76d0b4c7e81","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Approved-by-the-European-Commission-for-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-Whose-T-4UTE0.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745338\/revisions"}],"predecessor-version":[{"id":3674745,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745338\/revisions\/3674745"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745338"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}